EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
Garcia-Manero, G., Platzbecker, U., Santini, V., Zeidan, A., Fenaux, P., Komrokji, R., Shortt, J., Valcarcel, D., Jonasova, A., Dimicoli-Salazar, S., Tiong, I.S., Lin, C.-C., Li, J., Zhang, J., Giuseppi, A.C., Kreitz, S., Pozharskaya, V., Keeperman, K., Rose, S., Prebet, T., Degulys, A., Paolini, S., Cluzeau, T., Porta, M. Della
Published in Leukemia research reports (2024)
Published in Leukemia research reports (2024)
Get full text
Journal Article
P778: LONG‐TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER‐RISK MYELODYSPLASTIC SYNDROMES (LR‐MDS) FROM THE MEDALIST TRIAL
Fenaux, P., Santini, V., Komrokji, R. S., Zeidan, A., Garcia‐Manero, G., Buckstein, R., Miteva, D., Keeperman, K., Holot, N., Zhang, J., Nadal, J. A., Rosettani, B., Yucel, A., Platzbecker, U.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article